IceCure Wins U.S. Patent for Next-Generation Cryoablation System; Stock Trading Up 10%

IceCure Medical Ltd. (Nasdaq: ICCM) has secured a Notice of Allowance from the U.S. Patent and Trademark Office for its innovative “Cryogenic System Connector.” This patented technology is a critical component of IceCure’s next-generation XSense™ cryoablation system, which uses liquid nitrogen to freeze and destroy tumors as an alternative to surgical removal.

The XSense™ system, along with its FDA-cleared cryoprobes, is positioned to address additional medical indications and expand its reach in the global tumor ablation market, valued at $1.67 billion in 2023. Several other patent applications for this technology are pending in key global markets.

“With over 50 issued patents and the ongoing development of next-gen systems, we remain leaders in cryoablation innovation,” said IceCure CEO Eyal Shamir, emphasizing the company’s commitment to strengthening its intellectual property as it grows commercially.

Earlier this month, IceCure’s ProSense® cryoablation system was featured in six global

studies at the 2024 European Society of Breast Imaging (EUSOBI) conference. The ICE3 trial, which demonstrated a 96.3% recurrence-free rate for low-risk breast cancer, won the EUSOBI 2024 Abstract Award. The THERMAC trial also highlighted cryoablation’s effectiveness, with a 94% complete ablation rate, earning the EUSOBI Young Physician Scientist Prize. These awards reinforce ProSense®’s potential as a leading alternative to surgery in the treatment of breast cancer.

IceCure continues to expand its global reach, with strong interest from medical professionals at EUSOBI eager to adopt its cryoablation technology.